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Abstract
Background: THADs are associated with a wide spec-
trum of hepato-biliary pathologies. The aim of this paper
is to find out the role of THADs in the imaging
assessment of biliary diseases. We performed a retro-
spective study to establish the frequency of arterial
phenomena in patients with specific biliary diseases.
Methods: Out of 1833 patients who underwent upper
abdomen biphasic CT (2003–2007), we selected those
with the following diagnoses: biliary duct dilation due to
extrahepatic obstruction (20 patients-group A), intrahe-
patic-hilar cholangiocellular-carcinoma (19 patients-
group B), and cholangitis (14 patients-group C). THAD
presence/pattern was assessed for each group. Patients
without any demonstrable clinical/imaging signs of liver/
biliary pathology (1124) were the control group.
Results: THADs were observed in 36/53 (67.9%) and
20/1124 (1.78%) in study and control groups respectively,
with significant association between each diagnostic
group and THAD patterns (P < 0.0001). Eleven out
of 20 (55%) group A patients showed peribiliary-THAD
around dilated biliary tracts; 15/19 (79%) group B
patients demonstrated portal involvement and sectorial-
THAD; 10/14 (71%) group C patients revealed poly-
morphous-THAD all along inflamed biliary duct.
Conclusions: However, THADs are complex phenomena,
their evaluation can be an additional diagnostic tool in
patients with a biliary pathology. Diffuse peribiliary,
sectorial, and polymorphous-THADs show a good rate
of correlation (P < 0.0001) with biliary duct ectasia,
portal infiltration, and cholangitis, respectively.
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Transient hepatic attenuation difference(s) (THAD) are
areas of healthy liver parenchymawhich appearhyperdense
only or mainly during the hepatic artery phase of spiral
computed tomography (CT) [1, 2]. THADs derive from an
increase in arterial blood supply, usually as a compensatory
reaction to a decrease in portal flow. Nowadays, THADs
are frequently observed as a consequence of the widespread
use of dynamic imaging studies [3, 4]. These phenomena
have been reported in literature prevalently associated with
hepatic pathologies. Few studies have pointed out the
relationships between arterial phenomena and biliary
pathology [5–7]. Biliary duct diseases have a wide clinical
spectrum with frequent challenging diagnoses. Imaging
techniques have an important role in the assessment of site
and cause of biliary obstruction, evaluation of biliary dila-
tion degree, and detection of nodular lesion(s). To find out
the role of THADs in the imaging of biliary diseases, we
designed a retrospective study in order to establish the fre-
quency of THADs in patients with specific biliary diseases
(dilation, cholangiocarcinoma, and inflammation) and to
identify couplings with associated patterns. The under-
standing of these phenomena could guide the radiologist
toward a more accurate diagnosis.
Materials and methods
Patient selection
Images of 1833 patients, who underwent biphasic CT
examinations of the upper abdomen at our Radiology
Department between October 2003 and June 2007, were
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revised on digital archives. All examinations were
performed because of clinical indications according to
standard procedure and all patients gave their written
consent after being informed about possible risks of
X-rays and contrast medium injection. Ethical committee
approval and patient consent for this retrospective study
were not required, as patient privacy was maintained and
patient care was not impacted.
Inclusion criteria are as follows.
Group A—Extrahepatic biliary obstruction without
signs of inflammation. The main bile duct was
considered dilated when ‡7 mm in patients younger
than 60 years, ‡9 mm in older patients, and ‡10 mm
in patients with previous cholecystectomy, and a cause
was detected [8]. The intrahepatic bile ducts were
considered dilated when visible.
Group B—Cholangiocarcinoma with or without biliary
duct dilation, with or without portal vein involvement
(thrombosis, stenosis, or encasement). Diagnosis was
always confirmed by pathological examination using a
specimen obtained at surgery or during interventional
treatment. Hilar tumors were classified according to
Bismuth classification by Endoscopic Retrograde
Cholangio-Pancreatography (ERCP) or MR cholan-
giography [9].
Group C—Cholangitis without biliary vessels dilation.
Diagnosis was made according to the following clini-
cal findings: symptoms and signs of infection (fever,
leukocytosis), pain in the right upper abdominal
quadrant, jaundice, serum bilirubin ‡2.5 mg/dL, high
serum alkaline phosphatase, and resolution after an
antimicrobial course [10]. If available, bile and/or
blood cultures were considered as well. These patients
underwent a CT examination within one week from
the onset of symptoms. To obtain a clear correlation
between THADs and biliary pathologic background,
patients affected by mixed pathology (e.g., intra/
extrahepatic biliary dilation and cholangitis) were not
included in the study group. Age, gender, and diag-
nosis were recorded for every patient. Diagnoses were
verified by consulting the patient, the referring clini-
cians, and/or the clinical folder. Patients without any
demonstrable clinical signs, laboratory findings, or
imaging involvement of the liver or biliary tree were
considered the control group.
Study and control groups
Out of 1833 patients, 53 (79 CT examinations), 30 men
and 23 women, age 42–89 years, mean 66 (13.7 SD)
years, met the inclusion criteria and were the study
group. The latter, demonstrated extrahepatic biliary
obstruction in 20 (group A), cholangiocarcinoma in 19
(group B), and cholangitis in 14 (group C). Ten patients
were excluded because they were affected by mixed
pathologies such as biliary duct dilation and clinical signs
of inflammation, 3 out of these with mass and portal
involvement as well. Those without any demonstrable
clinical signs, laboratory findings, or imaging involve-
ment of the liver or biliary tree (1124 patients) were
the control group, 526 men and 598 women, age
22–88 years, mean 62 (14.3 SD) years. The remaining 646
patients were excluded because they were affected by
hepatic pathologies (diffuse hepatopathies, 177 patients;
moderate to severe steatosis (‡30%) diagnosed by visual
grading criterion, 20 patients [11]; neoplastic lesions, 155
patients; benign lesions, 294 patients).
Imaging acquisition
CT examinations were performed using a single-row
scanner (Somatom Plus, Siemens, Erlangen, Germany).
Spiral scans were obtained cephalocaudally with section
thickness of 5/8 mm and pitch 1.5/1 (reconstruction
4.5/7 mm), matrix 512 9 512, 170 or 220 mAs and
120 kV. The entire liver parenchyma was scanned within
a single breath hold of about 20 s. Three acquisitions
were obtained: one before (unenhanced scan) and two
after intravenous injection of a bolus of 1.5 mL/kg body
weight of non-ionic iodinated contrast material (Ultra-
vist 370, Schering, Berlin, Germany) at a rate of 3 mL/s.
Contrast medium was administered by an automatic
injector (Envision CT, MedRad, Pavia, Italy). Hepatic
artery and portal vein phase CT scans started 30 and
75 s, respectively, after the beginning of contrast material
injection.
Image evaluation
All the images of the study group were reviewed and
reassessed by two radiologists, both experienced in body
imaging for more than 15 years and unaware of the diag-
nosis. Disagreements were resolved by consensus. The
presence and pattern of any arterial phenomenon were
identified. THADs were classified (Table 1) as previously
published [12]. Four different types of THADs were con-
sidered:
(1) Sectorial: arterialization areas, secondary to portal
hypoperfusion and then following the portal dichot-
omy, appear with a triangular shape and at least one
‘‘straight border’’ sign (i.e., a clear separation line
from the normally attenuating parenchyma) [1, 2, 12].
(2) Lobar: arterialization areas involving all or almost
all the segments of a hepatic lobe, usually caused by a
primary increase in arterial in-flow due to a large
benign lesion (sump effect or siphoning phenome-
non), following the arterial distribution.
(3) Polymorphous: arterialization areas that usually do
not follow the portal dichotomy and show various
shapes, without a straight border sign, in relation to
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the cause, such as aberrant blood supply, inflam-
mation, extrinsic compression, or percutaneous
treatment outcome.
(4) Diffuse: arterialization areas involving the entire
hepatic parenchyma (or at least large areas of it).
They show three different patterns on the basis of the
portal obstruction site: patchy (post-sinusoidal
blockade with trans-sinusoidal system opening),
central peripheral (pre-intra-sinusoidal obstacle with
peribiliary plexus opening), or peribiliary (peribiliary
plexus blockade).
In group B patients, detectable focal lesions, biliary
ectasia and portal involvement (thrombosis, stenosis, or
encasement) were noted. Stenosis was defined as
restricted portal lumen, encasement as lumen vanishing
into the mass and/or within dilated biliary duct during
vein phase acquisition [13].
Statistical analysis
All data were analyzed with the Stats Direct statistical
software, version 2.5.8 (Stats Direct Ltd. Bonville Chase
Altrincham CHESHIRE WA14 4QA UK). Continuous
data are presented as mean (SD); discrete variables
(categorical data) are given as percentages. Discrete
variables were compared by Chi-Square test (Yates-cor-
rected for 2 9 2 contingency tables), two-tailed Fisher’s
Exact Test, or Fisher–Freeman–Halton Exact Test,
where appropriate. A P-value <0.05 was considered
statistically significant.
Results
A statistically significant difference in the incidence
(P < 0.0001) of the arterial phenomena was observed
between patients of the study (67.9%) and the control
group (1.78%). Demographic features, diagnosis of
patients, and THAD characteristics are shown in Table 2.
Group A—Dilation
Out of 20 patients 11 (55%) had a THAD, which appeared
in 9 cases with a diffuse peribiliary linear railway-like
pattern (Fig. 1), while 2 patients showed a polymorphous,
more localized pattern, with globular enhancement
(Table 1). Four patients, all with choledocal stones (2
peribiliary and 2 polymorphous patterns THAD), under-
went a further CT examination from 15 days up to
3 months after stone removal, showing the disappearance
of the arterial phenomena (Fig. 1).
Group B—Cholangiocarcinoma
Out of the 19 patients 15 (78.9%) showed at least one
THAD. Four patients had a focal hepatic mass (21%), 7
biliary dilation (37%), and 8 both a mass and biliary
ectasia (42%). The mean mass dimension was 2.1 (1.1
SD) cm, ranging from 0.8 to 4.5 cm. Sectorial pattern
was found in 13 patients, all with portal branch stenosis
or encasement (Table 2) (Fig. 2). One patient with
complete hilum involvement and portal trunk thrombo-
sis showed a diffuse central peripheral pattern; one other
Table 1. Classification of transient hepatic attenuation differences
Type Focal lesion Morphology/pattern Pathogenenesis
Sectorial Yes Wedge or fan-shaped Secondary
No Wedge-shaped
Lobar Yes Lobar multi-segmental not sectorial Primary
Polymorphous No Various shape and size, marginal or central,
without a clear straight border sign
Secondary
Diffuse No Patchy Secondary
Central-peripheral
Peribiliary
Secondary: arterial hyperperfusion secondary to portal hypoperfusion; Primary: primary arterial hyperperfusion












A (9/11) 64 (13) Dilation 20 (0) 9 – Scattered 2 9
B (12/7) 67 (15) Mass 4 (3) – 2 Central-peripheral 1 – 1
Dilation 7 (5) 1 5 – 1
Mass + dilation 8 (8) – 6 – 2
C (7/7) 66 (15) Cholangitis 14 (0) – – Scattered 5 confluent 5 4
Group A: biliary tree dilation without clinical sign of inflammation. Mirizzi’s syndrome (2), ampullary carcinoma (2), choledocal stones (8),
pancreatic head carcinoma (8)
Group B: cholangiocarcinoma (classified according to Bismuth). Intrahepatic (7), Klatskin IIIB (4), Klatskin IV (8)
Group C: cholangitis without biliary duct dilation. After interventional procedure (4), in bile-digestive shunt (4), in gallstones (2), in duodenal
diverticulum (1), unknown cause (3)
Central peripheral pattern should be considered generalized form of sectorial pattern
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patient had dilated biliary vessels with peribiliary pattern
(Table 1). Six patients had more than one CT examina-
tion. Two patients (one with a mass and one with biliary
tree dilation) at a previous CT, performed 3 and
6 months before, showed only the arterial phenomenon
without biliary duct dilation and no detectable mass
(Fig. 3). Four patients with a mass and biliary ectasia,
who never underwent open surgery (two received a biliary
stent), showed a decrease in attenuation and in area of
THAD (Fig. 2) at a further CT performed 2–12 months
later.
Group C—Cholangitis
Of the 14patients 10 (71.4%) had aTHAD,which appeared
as various dimensioned spots, roughly globular and irreg-
ularly distributed along biliary vessels (polymorphous
pattern), scattered in 5 cases (Fig. 4), and confluent in the
other 5 (Fig. 5). No clinical differences were observed
between these patients and the other group C ones. Four
patients, after clinical resolution of cholangitis, underwent
further CT examinations from 15 days up to 3 months,
which demonstrated THAD vanishing (Fig. 5).
Statistical analysis demonstrated a significant rela-
tionship between groups and THAD patterns
(P < 0.0001). Post hoc analysis indicated the significant
difference between each group vs. another group (A vs.
B + C; B vs. A + C; C vs. A + B; P < 0.0001).
Discussion
Pathophysiological studies have demonstrated commu-
nication between the two hepatic inflows (70% portal
vein, 30% hepatic artery) mainly through the sinusoid
system and peribiliary plexus. These shunts attempt to
Fig. 1. A 59-year-old man with choledochal stones.
(A) Unenhanced CT scan shows intrahepatic biliary tree
dilation (arrows). (B), (C) CT artery phase scans reveal THAD
around the biliary ducts (arrowheads). (D) CT 2 months after
the removal of stones shows no arterial phenomena.
S. Pradella et al.: THAD and biliary disease 629
locally compensate for reduced portal inflow under the
action of autonomic nervous system and humoral
mediators (primarily adenosine and prostacycline) [2].
Thus, an important increase in arterial inflow can be
demonstrated only in the parenchymal area involved by
acute portal inflow reduction. The arterial reaction is
proportional to the portal lessening; however, even a
slight decrement in portal inflow determines an impor-
tant arterial increment [1, 14]. The THAD is the CT
appearance of the described events.
The main shunting system involved in our series is the
peribiliary plexus, which surrounds themain bile ducts like
a mesh, allowing the passage of a minor, non-quantifiable
fraction, of the portal inflow into the sinusoid system,
while themain part of portal blood passes directly from the
triads to the sinusoids. The peribiliary plexus, lacking
muscular walls, collapses when the bile duct dilates. So,
functional impairment or failure of the plexus causes a
decrease in blood inflow from the portal vein into the
sinusoid system which induces a slight arterial compen-
sation due to the only partial blockade of portal inflow
[1, 15]. When biliary pressure decreases as a result of
drainage, the bile duct becomes narrower with consequent
decompression of the peribiliary plexus: portal flow is
restored and the arterial phenomena vanish (Fig. 1).
However, if stasis persists, the arterial phenomena slowly
disappear as well, due to receptor saturation and collateral
shunt consolidation [1, 2]. Both clinical experience and the
literature indicate that the outcome in case of biliary stasis
is atrophy of the involved parenchyma [1, 2, 15].
In our series, we found a greater prevalence of
THADs (68%) in patients with biliary diseases than in
Fig. 2. An 80-year-old women with cholangiocellular carci-
noma. (A) Unenhanced CT scan reveals a hypodense mass
in the left hepatic lobe and biliary tree dilation. (B) On CT
artery phase a sectorial hyperdense area (arrow) surrounding
the mass is visible. (C) Sagittal plane reconstruction confirms
the sectorial shaped THAD (arrowheads). (D) Two months
later, the mass persisting, at artery phase CT, the THAD
appears smaller and with a weaker visual intensity.
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Fig. 3. A 63-year-old man with cholangiocellular carcinoma. (A) CT artery phase demonstrates only a sectorial hyperdense area
without a clear explanation. (B) Three months later, at artery phase CT, a bile ducts dilation can be observed as well (arrow).
Fig. 4. A 64-year-old man with cholangitis. (A), (B) CT artery phase shows polymorphous THADs (arrows) without dilation of
biliary vessels. (C) Three months later, after therapy, at artery phase CT, the arterial phenomena disappeared.
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control subjects (1.8%). When an infiltrative pathology
with portal involvement was considered (group B), the
incidence reached 79%. These findings indicate that
biliary tree diseases cause perfusional abnormalities of
liver parenchyma in the early phase on dynamic CT. We
also found a significant correlation between each group
of alterations and a specific THAD pattern.
We detected a peribiliary pattern in more than half of
the patients (55%) with biliary duct dilation (group A)
(Fig. 1). This is due to functional impairment of the
peribiliary plexus, andwhen the biliary pressure decreases,
the portal inflow is restored and the THAD disappears or
lessens (as we observed in the four cases in which control
examinations were available) (Fig. 1). This reversibility,
and the non-quantifiable amount of portal inflow to the
sinusoids passing through the peribiliary plexus, almost
certainly with wide inter/intra-individual variability,
could explain the inconstancy of THAD in the patients
with dilated biliary duct.
The peribiliary plexus plays a main role when the
pathological background is a biliary duct inflammation
(group C), as well. We observed a polymorphous pattern
in 72% of our patients (Fig. 5). The pattern and inci-
dence we detected, agree with what previous investiga-
tors found (85%) [10]. However, they suggested that the
arterial phenomenon was induced by inflammatory
enlargement of the plexus, whereas we believe that
THAD patterns derive from impairment of the peribil-
iary plexus attributable to inflammatory edema. The
dissimilarity between THAD pattern observed in dilation
and that detected in inflammation (without dilation) of
biliary duct is, in our opinion, related to the spread of
inflammatory mediators by contiguity with consequently
more evident arterial pattern. The wide variability in
extension and severity of cholangitis presentation can
explain the polymorphous pattern and absence of any
arterial phenomenon (4 patients in our series), as well.
When inflammation is relieved after successful therapy,
Fig. 5. An 84-year-old man with cholangitis. (A), (B) CT
artery phase demonstrates multiple globular spots around
non-dilated biliary tree (arrows). (C) On portal phase, arterial
phenomena vanish. (D) Fifteen days later, after therapy, at
artery phase CT, the arterial phenomena disappeared.
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THADs consequently disappear, as demonstrated in
other 4 patients in our series (Fig. 5).
The most prevalent THAD pattern in patients with
cholangiocarcinoma (group B) is represented by sectorial
arterialization i.e., a roughly triangular shaped hyperat-
tenuating area with the apex directed towards the hepatic
hilum (Fig. 2). Noteworthy, while peribiliary arteriali-
zation is specific of biliary dilation and inflammation,
sectorial THADs are not only due to cholangiocarci-
noma. Actually, sectorial THADs are the most frequent
arterialization phenomena associated with non-nodular
and nodular (prevalently malignant masses) hepatic
pathologies. As a general rule, arterial phenomena with
sectorial morphology are secondary to portal hypoper-
fusion due to portal branch stenosis, encasement,
thrombosis or by flow diversion caused by an arterio-
portal shunt.
Then, in case of cholangiocarcinoma, if a hepatic
mass, with or without biliary duct dilation, is present,
sectorial high attenuation THAD is determined by
malignant involvement of the portal branches and
peribiliary sites [1, 2, 12]. In fact in 8/11 patients of our
series with mass and portal involvement we observed a
sectorial pattern. However, in 5/7 patients with biliary
duct dilation without any detectable mass, but with sign
of portal encasement, we found a sectorial shaped
THAD as well. We postulate that in these cases the
arterial phenomenon is caused by a focal lesion, not
detectable for dimensional or contrastographic reasons,
but already inducing a portal inflow blockade. So, arte-
rialization may suggest an underlying abnormality and
precede the CT detection of the nodular lesion. This
seems to be confirmed by the 2 cases with a mass and
biliary tree dilation (Fig. 3), in which the first CT scan
showed only the sectorial arterial phenomenon. In the
only case in which the obstacle determined by cholangi-
ocarcinoma is at the level of the portal axis with
thrombosis of both main branches, the observed THAD
pattern is a ‘‘central-peripheral’’ type, which can be
considered as the generalized equivalent of the sectorial
arterialization. We interpreted the unique cholangiocar-
cinoma presented with mass and dilation associated with
a non-sectorial THAD as a non-infiltrative nodule and
then as a neoplasm inducing only biliary duct dilation
determining a peribiliary pattern. Similarly, we postulate
that the lack of major portal infiltration could also
clarify the absence of any THAD in 2 of our selected
cases [1, 2]. In other 2 patients with portal involvement
but without any perceptible THAD, we believe the
absence of arterial phenomena a consequence of receptor
saturation and collateral shunt consolidation with
resulting parenchymal involution. This looks to be vali-
dated by the 4 cases of sectorial THADs vanishing or
disappearing (Fig. 2), despite the permanence of the
cause.
The patients affected by mixed pathology were not
included in the study group in order to avoid confusing
CT patterns. In fact, in these cases we detected over-
lapping appearance of THAD’s patterns. When peribil-
iary plexus is impaired due to duct dilation and
inflammation, the resultant CT pattern appears mainly
as a diffuse arterial background (i.e., great confluent
spots). If a mass with portal involvement is also present,
the major portal obstruction determines sectorial
THAD(s) as well.
In conclusion, although our series is limited, it indi-
cates the existence of three main THAD’s patterns which
can represent additional diagnostic tools: diffuse linear
and polymorphous peribiliary types, exclusively found in
patients with biliary dilation and inflammation, respec-
tively; sectorial high attenuation type, typically due to
portal involvement and in our study related to cholan-
giocarcinoma.
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